Please use this identifier to cite or link to this item:
https://er.nau.edu.ua/handle/NAU/50508| Title: | COVID vaccine: supply chain challenges |
| Other Titles: | Вакцина COVID: проблеми з ланцюгами поставок |
| Authors: | Kisera, Tetyana Кісера, Тетяна Олегівна |
| Keywords: | supply chain vaccine delivery challenges COVID pandemic ланцюг поставок вакцина проблеми доставки пандемія COVID |
| Issue Date: | 8-Apr-2021 |
| Publisher: | National Aviation University |
| Citation: | Kisera T.O. COVID vaccine: supply chain challenges // Flight. Modern problems of science: abstracts of the XXI International scientific-practical conference of applicants for higher education and young scientists. - National Aviation University. - Kyiv, 2021. - P. 39-42 |
| Abstract: | The Covid pandemic paused the development of the world economy for quite some time. Experts link the beginning of recovery with the speed and quality of vaccination. That’s why the aim of the paper to analyze different logistics and supply chain questions, connected to the procedure of delivering and handling vaccines in Ukraine. Preservation and proper transportation are directly proportional to a safe vaccine. Therefore, the table 1 refers main data based on information from official web sites about 5 vaccines that have passed the 3rd phase of clinical testing / evaluation. The Sputnik B vaccine will be excluded from this list because it is prohibited by law in Ukraine. Пандемія Ковіда на деякий час зупинила розвиток світової економіки. Експерти пов'язують початок одужання із швидкістю та якістю вакцинації. Ось чому мета статті - проаналізувати різні питання логістики та ланцюга поставок, пов’язані з процедурою доставки та обробки вакцин в Україні.Збереження та належне транспортування прямо пропорційні безпечній вакцині. Тому в таблиці 1 наводяться основні дані на основі інформації з офіційних веб-сайтів про 5 вакцин, які пройшли 3-й етап клінічного тестування / оцінки. Вакцина Sputnik B буде виключена із цього списку, оскільки вона заборонена законом в Україні. |
| Description: | 1. Mia Rabson (2021). From science to syringe: COVID-19 vaccines are miracles of science and supply chains. CTV News (Bell Media). (Date of appeal: 20.03.2021) [Electronic resource]. - Access mode:https://www.ctvnews.ca/health/coronavirus/from-science-to-syringe-covid-19-vaccines-are-miracles-of-science-and-supply-chains-1.5327003 2. Reporting by Michael Shields; editing by Jason Neely (2021). Lonza gets Swiss OK to start Moderna vaccine production –paper. Reuters. (Date of appeal: 20.03.2021) [Electronic resource]. - Access mode:https://www.reuters.com/article/health-coronavirus-swiss/lonza-gets-swiss-ok-to-start-moderna-vaccine-production-paper-idINKBN2980CK?edition-redirect=in 3. Moderna COVID-19 Vaccine. (Date of appeal: 20.03.2021) [Electronic resource]. - Access mode:https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html 4. Mayank Kumar (2020). Covid-19 vaccine: Serum Institute signs up for 100 million doses of vaccines for India, low and middle-income countries. (Date of appeal: 20.03.2021) [Electronic resource]. - Access mode:https://www.financialexpress.com/lifestyle/health/covid-19-vaccine-serum-institute-signs-up-for-100-million-doses-of-vaccines-for-india-low-and-middle-income-countries/2047884/ 5. David Erskine (2021) Transporting the AstraZeneca COVID-19 Vaccine from PCN designated sites to end user locations, patients’ homes and within the PCN Grouping. (Date of appeal: 20.03.2021) [Electronic resource]. - Access mode:https://www.sps.nhs.uk/articles/transporting-the-astrazeneca-covid-19-vaccine-from-pcn-designated-sites-to-end-user-locations-patients-homes-and-within-the-pcn-grouping/ 6. Choong, Jerry (2021). "Health Ministry: Malaysia secures 18.4 million doses of Russian, Chinese Covid-19 vaccines". The Malay Mail. (Date of appeal: 20.03.2021) [Electronic resource]. - Access mode:https://www.malaymail.com/news/malaysia/2021/01/26/health-ministry-malaysia-secures-18.4-million-doses-of-russian-chinese-covi/1944232 7. Peter Jamison (2021). In a virus-ravaged city, nearly 400 million vaccine doses are being made — and shipped elsewhere. (Date of appeal: 20.03.2021) [Electronic resource]. - Access mode:https://www.washingtonpost.com/dc-md-va/2021/02/22/vaccine-baltimore-emergent-biosolutions-covid/ |
| URI: | https://er.nau.edu.ua/handle/NAU/50508 |
| Appears in Collections: | Політ. Менеджмент та логістика. 2021 |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| КІСЕРА_Т_О - Тетяна Олегівна Кісера.pdf | Тези конференції | 347.38 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.